189 related articles for article (PubMed ID: 36085339)
21. Ketoconazole treatment in Cushing's syndrome: experience in 34 patients.
Sonino N; Boscaro M; Paoletta A; Mantero F; Ziliotto D
Clin Endocrinol (Oxf); 1991 Oct; 35(4):347-52. PubMed ID: 1752063
[TBL] [Abstract][Full Text] [Related]
22. Management and Medical Therapy of Mild Hypercortisolism.
Favero V; Cremaschi A; Falchetti A; Gaudio A; Gennari L; Scillitani A; Vescini F; Morelli V; Aresta C; Chiodini I
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768949
[TBL] [Abstract][Full Text] [Related]
23. Psychometric evaluation of the Cushing's Quality-of-Life questionnaire.
Nelson LM; Forsythe A; McLeod L; Pulgar S; Maldonado M; Coles T; Zhang Y; Webb SM; Badia X
Patient; 2013; 6(2):113-24. PubMed ID: 23575965
[TBL] [Abstract][Full Text] [Related]
24. Use of late-night salivary cortisol to monitor response to medical treatment in Cushing's disease.
Newell-Price J; Pivonello R; Tabarin A; Fleseriu M; Witek P; Gadelha MR; Petersenn S; Tauchmanova L; Ravichandran S; Gupta P; Lacroix A; Biller BMK
Eur J Endocrinol; 2020 Feb; 182(2):207-217. PubMed ID: 31804965
[TBL] [Abstract][Full Text] [Related]
25. Corticotropin-dependent Cushing's syndrome in older people: presentation of five cases and therapeutical use of ketoconazole.
Berwaerts JJ; Verhelst JA; Verhaert GC; Verhaegen AA; Abs RE
J Am Geriatr Soc; 1998 Jul; 46(7):880-4. PubMed ID: 9670876
[TBL] [Abstract][Full Text] [Related]
26. Long-acting pasireotide improves clinical signs and quality of life in Cushing's disease: results from a phase III study.
Lacroix A; Bronstein MD; Schopohl J; Delibasi T; Salvatori R; Li Y; Barkan A; Suzaki N; Tauchmanova L; Ortmann CE; Ravichandran S; Petersenn S; Pivonello R
J Endocrinol Invest; 2020 Nov; 43(11):1613-1622. PubMed ID: 32385851
[TBL] [Abstract][Full Text] [Related]
27. The effect of pulsatile human corticotropin-releasing hormone administration on the adrenal insufficiency that follows cure of Cushing's disease.
Avgerinos PC; Nieman LK; Oldfield EH; Loughlin T; Barnes KM; Loriaux DL; Cutler GB
J Clin Endocrinol Metab; 1989 May; 68(5):912-6. PubMed ID: 2541160
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of Osilodrostat in Paraneoplastic Cushing Syndrome: A Real-World Multicenter Study in France.
Dormoy A; Haissaguerre M; Vitellius G; Do Cao C; Geslot A; Drui D; Lasolle H; Vieira-Pinto O; Salenave S; François M; Puerto M; Boullay HD; Mayer A; Rod A; Laurent C; Chanson P; Reznik Y; Castinetti F; Chabre O; Baudin E; Raverot G; Tabarin A; Young J
J Clin Endocrinol Metab; 2023 May; 108(6):1475-1487. PubMed ID: 36470583
[TBL] [Abstract][Full Text] [Related]
29. Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study.
Pivonello R; Petersenn S; Newell-Price J; Findling JW; Gu F; Maldonado M; Trovato A; Hughes G; Salgado LR; Lacroix A; Schopohl J; Biller BM;
Clin Endocrinol (Oxf); 2014 Sep; 81(3):408-17. PubMed ID: 24533697
[TBL] [Abstract][Full Text] [Related]
30. Updates in adrenal steroidogenesis inhibitors for Cushing's syndrome - A practical guide.
Varlamov EV; Han AJ; Fleseriu M
Best Pract Res Clin Endocrinol Metab; 2021 Jan; 35(1):101490. PubMed ID: 33707082
[TBL] [Abstract][Full Text] [Related]
31. Therapy of Cushing's syndrome with steroid biosynthesis inhibitors.
Engelhardt D; Weber MM
J Steroid Biochem Mol Biol; 1994 Jun; 49(4-6):261-7. PubMed ID: 8043488
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness versus efficacy: the limited value in clinical practice of high dose dexamethasone suppression testing in the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome.
Aron DC; Raff H; Findling JW
J Clin Endocrinol Metab; 1997 Jun; 82(6):1780-5. PubMed ID: 9177382
[TBL] [Abstract][Full Text] [Related]
33. [Salivary cortisol in adrenal diseases].
Løvås K; Husebye ES
Tidsskr Nor Laegeforen; 2007 Mar; 127(6):730-2. PubMed ID: 17363984
[TBL] [Abstract][Full Text] [Related]
34. Adrenal Cushing's Syndrome Treated With Preoperative Osilodrostat and Adrenalectomy.
Malik RB; Ben-Shlomo A
AACE Clin Case Rep; 2022; 8(6):267-270. PubMed ID: 36447826
[TBL] [Abstract][Full Text] [Related]
35. Effect of withdrawal of somatostatin plus growth hormone (GH)-releasing hormone as a stimulus of GH secretion in Cushing's syndrome.
Leal-Cerro A; Soto A; Martínez MA; Alvarez P; Isidro L; Casanueva FF; Dieguez C; Cordido F
Clin Endocrinol (Oxf); 2002 Dec; 57(6):745-9. PubMed ID: 12460324
[TBL] [Abstract][Full Text] [Related]
36. Late-night salivary cortisol as a screening test for Cushing's syndrome.
Raff H; Raff JL; Findling JW
J Clin Endocrinol Metab; 1998 Aug; 83(8):2681-6. PubMed ID: 9709931
[TBL] [Abstract][Full Text] [Related]
37. Subclinical Cushing's syndrome.
Reincke M
Endocrinol Metab Clin North Am; 2000 Mar; 29(1):43-56. PubMed ID: 10732263
[TBL] [Abstract][Full Text] [Related]
38. Different therapeutic efficacy of ketoconazole in patients with Cushing's syndrome.
Engelhardt D; Jacob K; Doerr HG
Klin Wochenschr; 1989 Feb; 67(4):241-7. PubMed ID: 2538676
[TBL] [Abstract][Full Text] [Related]
39. Mifepristone (RU 486) in Cushing's syndrome.
Johanssen S; Allolio B
Eur J Endocrinol; 2007 Nov; 157(5):561-9. PubMed ID: 17984235
[TBL] [Abstract][Full Text] [Related]
40. Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing's syndrome: a 15-year retrospective study.
Di Dalmazi G; Vicennati V; Garelli S; Casadio E; Rinaldi E; Giampalma E; Mosconi C; Golfieri R; Paccapelo A; Pagotto U; Pasquali R
Lancet Diabetes Endocrinol; 2014 May; 2(5):396-405. PubMed ID: 24795253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
